These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28087743)

  • 1. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
    Lüscher TF
    Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
    [No Abstract]   [Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 4. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do PCSK9 inhibitors reduce cardiovascular events?
    Kolber MR; Nickonchuk T; Turgeon R
    Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099
    [No Abstract]   [Full Text] [Related]  

  • 8. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors.
    Marco-Benedí V; Jarauta E; Pérez-Calahorra S; Bea AM; Civeira F
    Clin Investig Arterioscler; 2019; 31(2):89-92. PubMed ID: 30738610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer cholesterol-lowering agents: What you must know.
    Firnhaber JM
    J Fam Pract; 2018 Jun; 67(6):339;341;344;345. PubMed ID: 29879234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
    Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
    Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 14. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.
    Hofer TP; Sussman JB; Hayward RA
    Ann Intern Med; 2016 May; 164(10):683-4. PubMed ID: 26857151
    [No Abstract]   [Full Text] [Related]  

  • 17. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL-cholesterol: The lower the better.
    Pedro-Botet J; Pintó X
    Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():16-27. PubMed ID: 31813618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
    Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
    Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.